Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune ...

Bavarian Nordic files clinical data to EMA to extend mpox and smallpox vaccine approval to children aged from 2 to 11 years: Copenhagen, Denmark Saturday, March 28, 2026, 12:00 Hr ...

Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN ...

Emergent BioSolutions was awarded a contract worth about $54 million to supply the Administration for Strategic Preparedness and Response with additional doses of Vigiv, a treatment for smallpox ...

European Medicines Agency’s (EMA) committee for human medicines, CHMP, has recommended that Tecovirimat SIGA should no longer be used for the treatment of mpox. This recommendation does not affect the ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that Tecovirimat SIGA ...

From an enslaved Bostonian who helped save smallpox victims to scientists behind the COVID-19 vaccine, National Doctors' Day ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV ...

India has a long history of eradicating and eliminating serious disease burdens through well-planned and well-executed ...

In the early years (1979–1984), measles vaccination coverage was less than 2%. From a time when children relied on nature and fate, the country began a steady transformation in the 1990s. 1990: ...

The EMA's human medicines committee has recommended approval of Amgen's bispecific T-cell engager (BiTE) – Imdylltra – as a second-line treatment option for extensive-stage small cell lung cancer ...